Comparative Pharmacology
Head-to-head clinical analysis: MORPHINE SULFATE AUTOINJECTOR versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MORPHINE SULFATE AUTOINJECTOR versus WESTADONE.
MORPHINE SULFATE (AUTOINJECTOR) vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate is a full opioid agonist that binds to mu-opioid receptors (MOR) in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain. It also activates delta and kappa receptors, contributing to analgesia and side effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Adult: 2–5 mg IV every 5–10 minutes as needed for pain; 10 mg IM every 4 hours as needed for pain. For autoinjector, typical dose is 5–10 mg IM or SC once.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged to 3-6 hours in elderly, neonates, or patients with hepatic/renal impairment. Clinical context: Half-life does not correlate directly with duration of analgesia; analgesic duration is 4-6 hours due to slow CNS equilibration.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal: 90% of morphine and its metabolites (morphine-3-glucuronide, morphine-6-glucuronide) are excreted in urine. About 7-10% is eliminated via bile and feces. Enterohepatic recirculation occurs.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist